Delving into the Latest Updates on BREAST CANCER RIPTAC (Halda Therapeutics) with Synapse

Overview

Basic Info

Drug Type

Regulated induced proximity targeting chimeras (RIPTAC)

Synonyms-

Target-

Mechanism-

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Hormone Receptor Positive Breast Adenocarcinoma

Inactive Indication-

Originator Organization

Halda Therapeutics LLCStartup

Active Organization

Halda Therapeutics LLCStartup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Regulated induced proximity targeting chimeras (RIPTACs), a new class of heterobifunctional molecules, show promise in specifically targeting and eliminating cancer cells while leaving healthy cells unharmed. As a groundbreaking drug discovery approach, RIPTACs work by forming a stable complex with two proteins, one specifically found in cancer cells (target protein, TP) and the other pan-essential for cell survival (effector protein, EP), selectively disrupting the function of the EP in cancer cells and causing cell death. Interestingly, the TPs need not be linked to disease progression, broadening the spectrum of potential drug targets. This review summarizes the discovery and recent advances of the RIPTAC strategy. Additionally, it discusses the associated opportunities and challenges as well as future perspectives in this field.

100 Deals associated with BREAST CANCER RIPTAC (Halda Therapeutics)

Login to view more data